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Abstract: Based on the biomolecular expression; cytogenetic and flow-cytometric results; minimal residual 
disease (MRD) without any clinical or hematological connections; is considered to be very important for the type 
of the treatement used. The treatment is in this way adapted to these results. The new drugs recently introduced 
in the protocols and the scientific based therapy; set the ALL curability rate to higher levels (over 80%). This 
study is trying to introduce in our medical practice different techniques that will allow us to investigate the 
MRD. Our efforts to allign to the european management of  ALL in children; is seen by the international 
scientific community as a professional and ethical responsability regarding our patients; who have the right to a 
healthy life; like any other european patient. Every year in our Clinic; we have about 70 new cases of leukemia; 
from which a number of 30-35 cases are represented by ALL. We started this study using the cytogenetical analysis 
and the fluorescence in situ hybridization (FISH) technique in 50 cases (35 new cases; 15 old cases or relapses). For 
the beginning; we used four different molecular probes which are important for the identification of the most 
frequently gene rearrangements in ALL: t(12;21)(p13;q22); t(9;22)(q34;q11); t(4;11)(q21;q23); t(8;14). Patients 
enrolled in this study have been investigated cytologenetical; by the banding method. In this case the   
chromosomes were GTG banded; and we used lymphocytes cultures obtained from peripherical blood and/or bone 
marrow. We found chromosomal abnormalities like: abnormalities of the chromosomal numbers (polyploidy; 
pseudoploidy; hyperploidy; hypoploidy) and abnormalities of the chromosomal structure (markers; deletions; 
duplications; and translocations which are the most important because they represent indicators of fatal prognosis). 
This complex study; including investigations of classical cytogenetics; techniques of molecular cytogenetics 
(fluorescence in situ hybridisation) and other investigations like (multiparametric flow-cytometry; and molecular 
methods) allowed us to do an high-sensitive evaluation of the MRD; and determined an increase rate of curability 
in this disease. 
 
INTRODUCTION 
 
Leukemias represent an heterogenous group of malignant diseases of the hematopoietic 
cells; who have a rapid and fatal evolution in the absence of the specific treatment. In 
Romania at this moment it is not performed the routine cytogenetical and molecular diagnosis 
of the patients with ALL; and this thing makes impossible the correct framing into a risk 
group of these patients. In this study we will do morphological; immunophenotypical; 
cytogenetical tests and investigations of molecular genetics for two reasons: first; to make a 
correct diagnosis of the disease; and second; to identify biological markers; useful in 
monitoring the MRD. These investigations will allow us to choose the best therapeutical 
solutions for the patients. 
Because in the flow cytometry laboratory from the III Pediatric Clinic from Timisoara; 
are used techniques of flow-cytometry; which allow the routine diagnosis of all the ALL 
cases; the complete investigations for the evaluation and monitoring of MRD; gave us the 
opportunity to make a step forward at an higher level; of correlating the treatment regimes 
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with the relapsing risk; which has a major impact in increasing the curability rate (1). At the 
beginning of the study; the laboratory had a BD Facs Caliber flow-cytometer with three 
colours; produced in year 2005. Another research project; made possible a new acquisition of 
the fourth colour; which helps us to detect the residual leukemical populations with an 
increased sensitivity indicator. In addition; this new acquisition improved the sensitivity 
measurment of the lymphocitar populations and of the CD34 before the bone marrow 
transplant; things that increased the competence of our Clinic in the ALL therapy in children; 
and therefore; increased the curability rate of the disease (2). 
The new acquisition imposed some activities:  
• To elaborate a clinical protocol for the selection of the patients; and the 
implementation of some strategies regarding the collection; preservation and handling of the 
biological samples.  
• To establish the combinations of monoclonal antibodies with an important relevance 
• To implement some laboratory methods to examine the biological samples obtained 
from the peripheral blood and/or bone marrow. 
• To elaborate an analyzing protocol for the results obtained by flow-cytometry 
techniques 
• To evaluate the preliminary results and their spreading at national and international 
level (scientifically communications; published articles). 
• The standardization of the investigating methods and technologies to increase the 
MRD detection sensitivity ( to obtain some technical solutions which will allow us to use in 
clinic the best panel of investigations in ALL in children ) 
• At the end of the study; we will supervise the increase level of curability; the EFS rate; 
shortening period of hospitalization; the reduction rate of the complications through the MRD 
monitoring; and at last the correlation of the disease with the adequate therapeutic protocol. 
Our working protocol is correlated with other protocols from European laboratories; 
especially laboratories from Austria and Germany; which we have a good collaboration (3). 
 
MATERIAL AND METHOD 
 
Every year in our Clinic we have about 70 new cases of leukemia; from which a number of 
30-35 cases are ALL. In our study we want to investigate through morphological methods and 
techniques of molecular genetics and cytogenetics; a number of 50-60 cases of ALL per year (35 
new cases; 15-25 old cases or relapses). For this study we used four probes; characteristic to the 
most frequently chromosomal rearrangements in ALL:  
• translocation t(12;21)(p13;q22) – genetic  rearrangement TEL/AML-1 
• translocation t(9;22)(q34;q11) – genetic rearrangement  BCR-ABL 
• translocation t(4;11)(q21;q23) – genetic rearrangement  MLL-AF4  
• t (8;14) –  translocations of gene c-myc  
 The patients from enrolled in the study were cytogenetical investigated by the GTG 
banding method (standard karyotype). For the GTG banding method we used lymphocytes 
cultures from peripheral blood and/or bone marrow (4).  
The FISH protocol used in our laboratory is different from other protocols from European 
laboratories; but it is correlated with the protocol used in the laboratory from Giessen; Germany. 
Its validation requires multiple attempts and parallel applications of the probes on the same 
patient; in different laboratories (fig. 1). 
In accordance with the agreement between our laboratories; during the probation of the 
preparation; the probes are sent in Germany and analyzed by some German experts. 
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Fig. 1. Images of the signals that confirm/ infirm the chromosomal abnormalities 
 
RESULTS AND DISCUSIONS 
 
We identified some chromosomal abnormalities; like: abnormalities of the chromosomal 
numbers: polyploidy; pseudodiploidy; hyperploidy; hypoploidy (fig. 2- 4); and abnormalities of the 
chromosomal structure (markers; deletions; duplications; translocations between different 
chromosomes; translocations t(9;22) and t(4;11) representing indicators of fatal prognosis). Also; we 
identified 2 cases with translocations t(8;14) and t(1;19).  
 
Fig. 2. Most frequently rearrangements/translocations in ALL in children 
 
The molecular evaluation indicated a comparable proportion of patients with t(9;22)-
BCR-ABL mutation (1;28%) and a higher proportion of patients with t(14;11) MLL-AF4 
mutation (2;56%); in comparison with the medical literature (5). 
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Fig. 3. Karyotype with chromosomal modifications in ALL  
 (structural abnormalities in chromosomes: (4; 19) 
 
Fig. 4. Flow-cytometry image of ALL in children 
 
In conditions in which the concept of “genomic medicine” or post-genomic era; represent a 
reality at an international level; the study of MRD made for the first time in Timisoara; will 
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represent the beginning of a multidisciplinary working Group focused on the integrative study of 
the leukemias (6;7). The ALL and MRD results obtained by our research team; will cumulate 
with the results from other European Laboratories from Austria; Germany; Hungary; Spain; USA; 
France; Italy etc. Being such an ample study; we will supervise if the cytogenetical abnormalities 
reported in the medical literature are seen in our patients with the same frequency or; we need to 
use our own strategy regarding the probes that will be further utilized. 
 
CONCLUSIONS 
 
 It is an emerging need to develop in Romania new clinical and therapeutic methods; in those 
medical fields where patients need a long period of hospitalization and treatment; expensive 
treatments that finally don’t bring any improvements to the patients.  
 The scientific potential and the consequences of investigations by immunophenotyping 
techniques will bring the interest of young researchers in the domain; who will involve much 
more in these activities. 
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